MICROALBUMINURIA AS A FORECAST FACTOR FOR CARDIO-VASCULAR COMPLICATIONS AND A MARKER OF THERAPY EFFICACY IN PATIENTS WITH ARTERIAL HYPERTENSION
https://doi.org/10.20996/1819-6446-2008-4-1-51-55
Abstract
Aim. To assess the microalbuminuria (MAU) and vascular wall elasticity in patients with essential hypertension (HT) and evaluate the possibilities to reduce in fatal cardiovascular risk due to lisinopril (Listril, Dr Reddy’s) therapy.
Material and methods. 42 patients (60,3±0,83 y.o.) with HT were involved in the study. Pulse wave velocity was estimated by volume sphygmography. MAU levels were detected with micral-test (Roche Diagnostics, Germany). Patients received lisinopril as a first-step antihypertensive drug, if necessary the dose of lisinopril was increased or amlodipine was added. The treatment lasted for 12 weeks.
Results. MAU was revealed more often in patients with increased body mass index as compared with whole population of hypertensive patients. MAU was associated with increased vascular wall stiffness. Lisinopril therapy during 4 weeks allowed to reach target level of blood pressure (BP) in 42,9% of patients and decreased in MAU level by 54,5%. Therapy continuation during 12 weeks allowed to reach target level of BP in 90,4% of patients and reduce in fatal cardiovascular risk by 36,6%.
Conclusion. Lisinopril therapy resulted in significant reduction in BP, MAU and fatal cardiovascular risk in patients with HT.
About the Authors
L. A. Haisheva
Rostov State Medical University
Russian Federation
Russian Federation
L. I. Katelnitskaya
Rostov State Medical University
Russian Federation
Russian Federation
References
1. Агеев Ф.Т., Мареев В.Ю. Фозиноприл в лечении сердечно-сосудистых заболеваний. РМЖ 2000;8(2):94-9.
2. Алмазов В.А., Шляхто Е.В. Гипертоническая болезнь.Москва, 2000.118 с.
3. Арутюнов Г.П., Чернявская Т.К., Лукичева Т.И. и др. Микроальбуминурия и пути ее медикаментозной коррекции. Клин фармакол тер. 1999;3: 23-8.
4. Вандер А., Физиология почек. Санкт-Петербург, 2000.
5. Ермоленко В.М. Хроническая почечная недостаточность. В кн.: Нефрология. Руководство для врачей. Под ред. И.Е. Тареевой. М.: Ме- дицина, 1995. Т. 1. С. 322-90.
6. Лифштиц Н.Л., Кутырина И.М. Особенности лечения гипертонии при хронических диффузных заболеваниях почек. Materia Medica. 1995;2: 39-50.
7. Моисеев В. С. Ингибиторы АПФ и нефропатия. Клин фармакол тер.- 1997;6(4):67-9.
8. Мухин Н.А., Моисеев В.С., Кобалава Ж.Д. и др. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер арх. 2004;6:39- 46.
9. Преображенский Д.В., Сидоренко Б.А. Ингибиторы ангиотензин- превращающего фермента в лечении поражений почек различной этиологии. РМЖ 1998;6(24):19-25.
10. Преображенский Д.В., Сидоренко Б.А., Романова Н.Е., Шатунова И.М. Клиническая фармакология основных классов антигипертензивных препаратов. Consilium medicum. 2000; 2(3): 99-127
11. Профилактика, диагностика и лечение артериальной гипертонии. Российские рекомендации (2-ой пересмотр). Москва 2004 – 20 с.
12. Сагинова Е.А., Федорова Е.А., Фомин В.В. и др. Формирование поражения почек у больных ожирением. Тер. арх. 2005;5:36–41.
13. Элиот Г.Л. Применение ингибитора ангиотензинпревращающего фермента спираприла при хронической почечной недостаточности, гипертонии и диабетической нефропатии. Тер. архив 2000;10:2-6.
14. Asmar R., Benetos A., Topouchian J. et al. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension 1995;26(3):485-90.
15. Bonnet F, Marre M, Halimi JM et al. Waist circumference and the metabolic syndrome predict the development of elevated albuminuria in non-diabetic subjects: the DESIR Study. J Hypertens 2006; 24 (6):1157–63.
16. Cirillo M, Senigalliesi L, Laurenzi M et al. Microalbuminuria in nondiabetic adults: relation of blood pressure, body mass index, plasma cholesterol levels, and smoking: The Gubbio Population Study. Arch Intern Med 1998; 158 (17): 1933–9.
17. De Jong PE, Brenner BM. From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria. Kidney Int 2004; 66: 2109–18.
18. Jones CA, Francis ME, Eberhardt MS et al. Microalbuminuria in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 2002; 39: 445–59.
19. Liese AD, Hense HW, Doring A. et al. Microalbuminuria, central adiposity and hypertension in the non-diabetic urban population of the MONICA Augsburg survey 1994/95. J Hum Hypertens 2001; 15: 799–804.
20. Mogensen C.E. Renoprotective role of ACE inhibitors in diabetic nephropathy. Br. Heart J. 1994;72 (3 suppl.):38-45.
21. Mogensen C.E. Systemic blood pressure and glomerular leakage with particular reference to diabetes and hypertension. J. Intern. Med. 1994;235:297-316.
22. Munakata M, Nunokawa T, Yoshinaga K et al. Brachial-ankle pulse wave velocity is an independent risk factor for microalbuminuria in patients with essential hypertension – a Japanese trial on the prognostic implication of pulse wave velocity (J-TOPP). Hypertens Res 2006; 29 (7): 515–21
23. Nieuwdorp M, Mooij HL, Kroon J et al. Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes 2006; 55 (4): 1127–32.
24. Pedrinelli R, Giampietro O, Carmassi F et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994; 344: 14–8.
Review
For citations:
Haisheva L.A., Katelnitskaya L.I. MICROALBUMINURIA AS A FORECAST FACTOR FOR CARDIO-VASCULAR COMPLICATIONS AND A MARKER OF THERAPY EFFICACY IN PATIENTS WITH ARTERIAL HYPERTENSION. Rational Pharmacotherapy in Cardiology. 2008;4(1):51-55. (In Russ.) https://doi.org/10.20996/1819-6446-2008-4-1-51-55
Views:
632
Email this article 